Tyler Zemla

Also affiliated with Alliance Data (United States)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 22 papers. Top paper: “Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer”.

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer

JAMA Network Open(2022)10.1001/jamanetworkopen.2021.49040

N/A

3.5DataRank · unranked

127 citations

Fang‐Shu Ou, Tyler Zemla, Þorvarður R. Hálfdánarson, Heinz‐Josef Lenz, Rimini Breakstone +11 more

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

New England Journal of Medicine(2024)10.1056/nejmoa2403991

N/A

3.0DataRank · unranked

141 citations

Susan M. Geyer, Tyler Zemla, Michael V. Knopp, Spencer C. Behr, Sydney Pulsipher +19 more

Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer

Future Oncology(2021)10.2217/fon-2021-0753

N/A

0.901DataRank · unranked

30 citations

Karla V. Ballman, Linda McCall, Anuhya Kommalapati, Tyler Zemla, Anna Weiss +12 more

Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer

Clinical Lung Cancer(2022)10.1016/j.cllc.2022.04.004

N/A

0.662DataRank · unranked

19 citations

Xiaofei Wang, Christine M. Bestvina, Terence M. Williams, Greg Masters, Anurag Kumar Singh +10 more

LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)

Annals of Oncology(2023)10.1016/j.annonc.2023.10.047

N/A

0.500DataRank · unranked

27 citations

Susan M. Geyer, F-S. Ou, Michael V. Knopp, Spencer C. Behr, Tyler Zemla +14 more

Association between physical activity and the time course of cancer recurrence in stage III colon cancer

British Journal of Sports Medicine(2023)10.1136/bjsports-2022-106445

N/A

0.494DataRank · unranked

26 citations

Chao Ma, Qian Shi, Donna Niedzwiecki, Tyler Zemla, Félix Couture +9 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.tps366

N/A

0.494DataRank · unranked

26 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +8 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.tps760

N/A

0.396DataRank · unranked

13 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +7 more

Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A021501)

Annals of Surgical Oncology(2024)10.1245/s10434-024-15670-6

N/A

0.381DataRank · unranked

6 citations

Tyler Zemla, Qian Shi, Diana Segovia, Syed A. Ahmad, Eileen M. O’Reilly +3 more

Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0447

N/A

0.360DataRank · unranked

10 citations

Chao Ma, Chen Yuan, Qian Shi, Brian M. Wolpin, Yin Zhang +19 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5100

N/A

0.345DataRank · unranked

9 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +8 more

Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma

Targeted Oncology(2022)10.1007/s11523-022-00914-w

N/A

0.330DataRank · unranked

8 citations

Vanessa Wookey, Tyler Zemla, Qian Shi, Zhaohui Jin, Steven R. Alberts +7 more

Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps3154

N/A

0.269DataRank · unranked

5 citations

Elad Sharon, Jennifer Le‐Rademacher, Erin Twohy, Tyler Zemla, Yujia Wen +8 more

Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance)

Cancer(2023)10.1002/cncr.35007

N/A

0.241DataRank · unranked

4 citations

Chao Ma, Qian Shi, Tyler Zemla, Félix Couture, Philip Kuebler +11 more

A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterations

The Oncologist(2025)10.1093/oncolo/oyaf069

N/A

0.232DataRank · unranked

3 citations

Tyler Zemla, Joleen M. Hubbard, John H. Strickler, Olumide B. Gbolahan, L. R. Wilson +6 more

Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4003

N/A

0.217DataRank · unranked

3 citations

Qian Shi, Charles S. Fuchs, Donna Niedzwiecki, Tyler Zemla, Priya Kumthekar +15 more

Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)

European Journal of Cancer(2025)10.1016/j.ejca.2025.115694

N/A

0.122DataRank · unranked

1 citations

Bert H. O’Neil, Sebastian Stintzing, Fang‐Shu Ou, Tyler Zemla, Donna Niedzwiecki +18 more

Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)

Epigenetics(2022)10.1080/15592294.2022.2058225

N/A

0.111DataRank · unranked

1 citations

Ming Yu, Yuhong Zhang, Fang‐Shu Ou, Tyler Zemla, Kelly Carter +8 more

Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib following Immunotherapy: A Real World Evidence Study

Cancers(2023)10.3390/cancers15194867

N/A

0DataRank · unranked

8 citations

Jennifer Gile, Michael H. Storandt, Zhaohui Jin, Tyler Zemla, Nguyen H. Tran +2 more

P-70 Outcomes following FGFR inhibitor therapy in patients with cholangiocarcinoma: Multi-center single institution cohort experience

Annals of Oncology(2022)10.1016/j.annonc.2022.04.160

N/A

0DataRank · unranked

0 citations

Vanessa Wookey, Tyler Zemla, Q. Shi, Tanios Bekaii‐Saab, Nguyen H. Tran +2 more

Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma

Cancers(2022)10.3390/cancers14215173

N/A

0DataRank · unranked

16 citations

Jennifer Gile, Mathias Earl Palmer, Tyler Zemla, Daniel H. Ahn, Tanios Bekaii‐Saab +4 more

Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931)

Cancer(2021)10.1002/cncr.33649

N/A

0DataRank · unranked

14 citations

Jun He, Jennifer Le‐Rademacher, Fang‐Shu Ou, Andrew Dodge, Tyler Zemla +8 more